Standout Papers
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy (2014)
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (2015)
- Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases (2007)
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (2015)
- A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD) (2013)
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary (2020)
- Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis (2010)
- Sudden death in hypertrophic cardiomyopathy: identification of high risk patients (2000)
- Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy (2010)
- Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance (2003)
- How to develop a more accurate risk prediction model when there are few events (2015)
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (2020)
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (2020)
- 2018 ESC Guidelines for the diagnosis and management of syncope (2018)
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (2015)
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary (2020)
- Cardiac Involvement in Fabry Disease (2021)
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial (2021)
Immediate Impact
6 from Science/Nature 192 standout
Citing Papers
Cardiac Amyloidosis Due to Transthyretin Protein
2024 Standout
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches
2023 Standout
Works of Perry Elliott being referenced
Contemporary and Future Approaches to Precision Medicine in Inherited Cardiomyopathies
2021
Evidence From Family Studies for Autoimmunity in Arrhythmogenic Right Ventricular Cardiomyopathy
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Perry Elliott | 28684 | 7028 | 5444 | 507 | 36.6k | |
| Stephen E. Epstein | 28307 | 7886 | 5983 | 523 | 45.6k | |
| William J. McKenna | 51710 | 11793 | 5349 | 696 | 58.3k | |
| Douglas L. Mann | 22373 | 11481 | 3597 | 442 | 38.1k | |
| Jeffrey A. Towbin | 35685 | 19344 | 5235 | 489 | 44.4k | |
| Patrick T. Ellinor | 25962 | 7042 | 2870 | 356 | 35.2k | |
| Gerhard Schüler | 24879 | 5240 | 6023 | 646 | 39.8k | |
| Joshua M. Hare | 12346 | 11023 | 1884 | 380 | 32.0k | |
| Toyoaki Murohara | 13705 | 17731 | 4402 | 1.2k | 44.1k | |
| Michael C. Fishbein | 15692 | 7403 | 3236 | 635 | 36.5k | |
| Richard Lee | 9967 | 16620 | 2482 | 389 | 36.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...